Oxford Vacmedix announces Research Collaboration with University of Oxford

Grant to fund research into novel applications and development of new cancer vaccines using the recombinant overlapping peptide technology developed by Dr. Shisong Jiang.

Oxford, UK – 9th July 2019

Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that research into its novel Recombinant Overlapping Peptide (ROP) technology will be carried out in the Department of Oncology at the University of Oxford.

The research will be funded by a grant made jointly between OVM and Changzhou Bioscience who hold a license from OVM to develop the ROP technology in China.

The grant will be for 5 years and will fund basic research into the mechanisms of action of the ROP cancer vaccines, the development of new vaccines and their use in combination with other immuneoncology (IO) agents. Under the terms of the agreement a research group will be set up in the Department of Oncology at the world leading medical school of the University of Oxford. The group will be led by Dr. Shisong Jiang, inventor of the ROP technology and founder of OVM and will collaborate with other leading academic institutions and hospitals in the UK, South Korea and in China.

William Finch, CEO of Oxford Vacmedix said:

“We are very pleased to be collaborating with Changzhou Bioscience to fund this programme. The Department of Oncology at the University has a world class reputation for research and we are confident that significant progress will be made to develop the ROP technology”

Professor Mark Middleton, Head of the Department of Oncology at the University of Oxford, added:

“We are delighted to have this funding for research to further the ground breaking work of Shisong Jiang and look forward to a productive collaboration in research, and potentially later in clinical trials where the new technology may provide significant benefit to cancer patients”

For more information or to arrange an interview, please contact:
William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 784074 | E: wfinch@oxfordvacmedix.com

About Oxford Vacmedix

Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience that is using the ROP platform in both diagnostics and adoptive cell therapy.

For more information, please visit: www.oxfordvacmedix.com/

About The Department of Oncology, University of Oxford

The Department of Oncology’s mission is to improve cancer care through research and teaching. There is a strong emphasis on translation, with established infrastructure to develop scientific insight toward clinical applications. The Department houses over 400 staff and postgraduate students – both clinical and non-clinical – and is one of the largest departments in the University of Oxford’s Medical Sciences Division. It is also home to the Institute for Radiation Oncology and hoses the Structural Genomics Consortium. One of the key aims for the Department is to bring together basic scientific and clinical research groups across Oxford – based in the Old Road Campus Research Building, the Radiobiology Research Institute, the Weatherall Institute for Molecular Medicine and the NHS Cancer and Haematology Centre – to apply knowledge of cancer and to develop research to improve the understanding of how to combat cancer in the most effective way possible.

For more information, please visit: https://www.oncology.ox.ac.uk